Vitrolife AB (publ) - Interim report Q3, 2025: Strong growth in Americas

Vitrolife AB (publ) reported its Q3 2025 results, highlighting a strong growth trajectory in the Americas despite overall challenges posed by currency fluctuations. The company recorded sales of SEK 835 million, reflecting a 3% rise in local currencies, though a 4% drop in SEK terms was noted, significantly impacted by a -7% currency effect. Excluding discontinued business operations, organic growth stood at 5%.

Regional sales performances varied, with a notable 11% increase in the Americas, contrasted against a -2% decline in EMEA and a modest 1% rise in APAC. The robust growth in the Americas underlines the effectiveness of Vitrolife's product strategy in this market. In terms of product groups, Consumables rose by 7%, Technologies by 8%, while Genetics saw a modest increase of 3% in local currencies.

The gross margin slightly improved to 58.9%, attributed to a favorable product mix, despite the adverse currency impacts. EBITDA for the quarter was SEK 253 million, resulting in a margin of 30.3%, although this was down from 33.4% in the previous year, largely due to currency effects. Operating cash flow showed an increase, reaching SEK 255 million.

For the first nine months of 2025, sales totaled SEK 2,548 million, reflecting a 1% growth in local currencies and a 4% decline in SEK, with a notable 4% organic growth when excluding discontinued business activities. Net income for Q3 amounted to SEK 102 million, with earnings per share at SEK 0.75. Overall, Vitrolife's Q3 results demonstrate resilience and strategic growth, particularly within the Americas, against a backdrop of currency volatility.

Vitrolife AB (publ) has showcased resilience in its Q3 2025 interim report, highlighting growth, particularly within the Americas, amid challenging headwinds from currency fluctuations. The company reported sales of SEK 835 million, representing a 3% growth in local currencies, although a 4% decline in SEK terms was largely attributed to a significant currency impact of -7%. This currency challenge emphasizes the importance of analyzing revenue performance in local terms to gauge underlying business strength.

Regional performance indicates that the Americas stood out with an impressive 11% growth in local currencies, offsetting weaker results in EMEA (-2%) and a stagnation in APAC (+1%). The organic growth of 5% in local currencies, excluding discontinued operations, is a positive sign, especially in Consumables and Technologies, which are showing growth rates of 7% and 8%, respectively.

Despite the solid revenue performance, the gross margin decreased to 58.1%, reflecting pressures from currency impacts, further illustrated by a decrease in EBITDA margin from 33.4% to 30.3%. Investors should keep a watchful eye on operational efficiencies and product mix enhancements to potentially alleviate margin pressures.

The company’s ability to generate a strong operating cash flow of SEK 255 million suggests robust operational health, despite declining net income of SEK 102 million. This underlines the importance of examining cash flow metrics as a gauge of sustainability.

In summary, while the current currency volatility poses risks, Vitrolife's strong foothold in the Americas and focus on innovative product offerings present a compelling growth narrative. Investors may consider a cautious approach, closely monitoring currency trends and operational strategies to enhance profitability. Balancing growth potential against external economic pressures will be key for assessing Vitrolife’s long-term investment viability.